{
  "slug": "prostate-cancer",
  "question": "What are the odds of dying from prostate cancer?",
  "category": "cancer",
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Prostate cancer sits in a strange place in the public mind. Most men have heard the \"1 in 8\" diagnosis figure — roughly the same headline number that attaches to female breast cancer — and most file it as a major threat on that basis. What the typical reader does not internalise is that prostate cancer has the largest gap between *incidence* and *mortality* of any common cancer: the great majority of men diagnosed with it do not die of it, and a meaningful share of older men carry histologically detectable prostate cancer that never causes symptoms at all. The screening literature has been openly arguing about this gap for over a decade, and the USPSTF has moved the recommendation twice in response. Public intuition has not caught up to that debate.\n",
    "rough_estimate": "50% of US adults are very or somewhat worried about getting cancer (Gallup, all sites); most men conflate the 1-in-8 diagnosis figure with the much lower death rate",
    "kind": "survey",
    "survey_source": {
      "title": "Cancer, Heart Disease Worries Eclipse COVID-19",
      "publisher": "Gallup",
      "url": "https://news.gallup.com/poll/358070/cancer-heart-disease-worries-eclipse-covid.aspx",
      "year": 2021
    }
  },
  "native": {
    "display": "~397,000 prostate cancer deaths per year globally (men)",
    "numerator": 397430,
    "denominator": 4000000000,
    "unit": "per year",
    "population": "global men, all ages"
  },
  "normalized": {
    "lifetime_us_adult": 0.02,
    "display": "1 in ~50 lifetime (global adult men)",
    "log_value": -1.699,
    "assumptions": "WCRF / IARC GLOBOCAN 2022 reports ~1.47 million new prostate cancer cases and ~397,430 deaths per year globally, making it the 4th most common cancer overall and the 2nd most common cancer in men. Women are not at risk (prostate is a male-only organ), so the population at risk is global adult men, roughly 3 billion. ~397,000 deaths per year across ~3 billion adult men is ~1.3 per 10,000 men per year on a flat-hazard basis, which compounds naively to ~0.8% over 60 adult years. That is a floor rather than a ceiling because prostate cancer mortality is heavily concentrated above age 70 — the SEER median age at prostate cancer death is 79 — so age-weighting pulls the realistic lifetime number higher, into the 1.5-2.5% range for a generic adult man alive today. The American Cancer Society’s direct US figure is 1 in 44 (~2.3%), and the SEER lifetime diagnosis figure is ~12.9% (roughly 1 in 8), with a long-run case fatality well under 20% driven by 5-year relative survival of 97.9%. Headline figure 0.02 (~1 in 50) for the global adult men baseline, bracketed by the direct US figure on the high side and by lower- incidence regions (notably East Asia) on the low side. Women are excluded from the headline because the risk is zero by anatomy; scope is global-adult- lifetime to match the cancer-lifetime sibling entries with the male-only population at risk flagged in the body text and regional breakdown.\n",
    "uncertainty": {
      "low": 0.012,
      "high": 0.028
    },
    "scope": "subgroup_lifetime"
  },
  "sources": [
    {
      "url": "https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/",
      "title": "Prostate cancer statistics",
      "publisher": "World Cancer Research Fund International",
      "source_type": "reputable_reference",
      "statistic": "1,467,854 new prostate cancer cases and ~397,430 deaths globally in 2022; 4th most common cancer worldwide and 2nd most common cancer in men",
      "excerpt": "\"There were 1,467,854 new cases of prostate cancer in 2022. [...] Prostate cancer is the 4th most common cancer worldwide. It is the 2nd most common cancer in men.\"\n",
      "source_date": "2024-05-01",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20241117074955/https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/",
      "calculation_notes": "WCRF republishes the IARC GLOBOCAN 2022 prostate cancer totals: ~1.47M new cases and ~397K deaths per year. Divided across ~3B adult men worldwide, that is ~1.3 per 10,000 per year on a flat-hazard basis. Age-weighting (prostate cancer mortality is concentrated above age 70, with a median age at death of 79 per SEER) pulls the realistic cumulative lifetime mortality near 1.5-2.5% globally. Used as the primary global headline and for the \"4th most common / 2nd in men\" framing in the body text. The ~3.7x ratio between global cases and deaths is the largest for any common cancer and is the central story of this entry.\n",
      "independence_note": "WCRF’s cancer statistics pages are a downstream republication of IARC GLOBOCAN 2022. Treated as partially dependent with any other IARC-derived source; used here because the direct IARC news release for GLOBOCAN 2022 does not break out prostate cancer totals in its text.\n"
    },
    {
      "url": "https://seer.cancer.gov/statfacts/html/prost.html",
      "title": "Cancer Stat Facts: Prostate Cancer",
      "publisher": "Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute",
      "source_type": "govt_report",
      "statistic": "~12.9% US lifetime risk of prostate cancer diagnosis; 5-year relative survival 97.9% (2015-2021); median age at death 79; ~313,780 new cases and ~35,770 deaths estimated for 2025; age-adjusted death rate declining ~0.6% per year",
      "excerpt": "\"Approximately 12.9 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2018–2021 data, excluding 2020 due to COVID.\"\n",
      "source_date": "2025-04-01",
      "source_accessed": "2026-04-11",
      "archive_url": "https://web.archive.org/web/20260413181914/https://seer.cancer.gov/statfacts/html/prost.html",
      "calculation_notes": "SEER gives direct US lifetime incidence of ~12.9% (the \"roughly 1 in 8\" that most men have heard). With 5-year relative survival of 97.9% and a median age at death of 79, the implied long-run case fatality is small: ~12.9% incidence multiplied by a roughly 15-20% long-run case fatality gives a US lifetime prostate-cancer-death probability near 2.0-2.5%, consistent with ACS’s direct \"1 in 44\" figure. Anchors the US row in the regional breakdown and the top of the Likelier uncertainty band. The 97.9% 5-year survival is the mechanism that creates the diagnosis/ death gap flagged in the body text — it is higher than the figure for any other common cancer.\n",
      "independence_note": "SEER (NCI) and IARC GLOBOCAN (WHO/WCRF) are methodologically independent compilation pipelines. SEER uses US vital registration and population- based cancer registries; IARC aggregates national registry data worldwide. The two are used here as independent anchors on the US and global ends of the regional breakdown.\n"
    },
    {
      "url": "https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html",
      "title": "Key Statistics for Prostate Cancer",
      "publisher": "American Cancer Society",
      "source_type": "reputable_reference",
      "statistic": "About 1 in 8 US men will be diagnosed with prostate cancer during their lifetime; about 1 in 44 will die of it; ~333,830 new cases and ~36,320 deaths projected for 2026",
      "excerpt": "\"About 1 in 8 men will be diagnosed with prostate cancer during their lifetime. [...] About 1 in 44 men will die of prostate cancer. [...] Prostate cancer risk is also higher in Black men in the US and the Caribbean. [...] About 6 in 10 prostate cancers are diagnosed in men who are 65 or older, and it is rare in men under 40.\"\n",
      "source_date": "2026-01-16",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260405152053/https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html",
      "calculation_notes": "ACS gives both the 1-in-8 diagnosis and the 1-in-44 death figure explicitly. The 5.5x gap between the two is the load-bearing fact for this entry and the main calibration story: readers reliably quote \"1 in 8\" as if it were a death rate, when it is in fact the incidence rate — the death rate is ~2.3%, an order of magnitude below what the headline implies. The age-skew (\"6 in 10 diagnoses at 65 or older\") and the race-disparity framing are used to support the body text and the regional_breakdown / personal_factor_multipliers blocks.\n",
      "independence_note": "ACS derives its US lifetime-probability figures from SEER incidence and mortality data. Treat these two as a single pipeline for US-specific numbers rather than as independent verification of each other.\n"
    },
    {
      "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening",
      "title": "Final Recommendation Statement: Prostate Cancer: Screening",
      "publisher": "US Preventive Services Task Force",
      "source_type": "govt_report",
      "statistic": "USPSTF recommends individual decision-making on PSA screening for men 55-69 (Grade C, upgraded from D in 2012); recommends against PSA screening for men 70+ (Grade D); notes 20-50% of screen-detected cases may be overdiagnosed",
      "excerpt": "\"The decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one. [...] The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older.\"\n",
      "source_date": "2018-05-08",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260322095529/https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening",
      "calculation_notes": "USPSTF is the authoritative US primary-care screening guideline. The 2018 move from a blanket Grade D (recommend against) to Grade C (individual decision) for men 55-69 was a direct response to the longer-term ERSPC trial follow-up, which showed screening prevents about 1.3 prostate cancer deaths per 1,000 men screened over 13 years and reduces metastatic disease by about 3 per 1,000. That is a real but modest mortality benefit, set against a 20-50% overdiagnosis rate. Used here as the authoritative basis for the overdiagnosis framing in the body text and the myth_framing: overrated tag — \"overrated\" in the sense that the headline incidence figure massively overstates the death risk, not that the disease itself is not a major cancer.\n",
      "independence_note": "USPSTF evidence synthesis is methodologically independent of the SEER/IARC incidence-registry pipelines; it aggregates RCT and cohort evidence on screening effectiveness. Treated as an independent source here for the screening and overdiagnosis claims.\n"
    },
    {
      "url": "https://pubmed.ncbi.nlm.nih.gov/38230766/",
      "title": "Cancer statistics, 2024",
      "publisher": "Siegel RL, Giaquinto AN, Jemal A / CA: A Cancer Journal for Clinicians",
      "source_type": "peer_reviewed",
      "statistic": "Prostate cancer mortality rates are approximately two-fold higher in Black men than in White men in the US, alongside stomach and uterine corpus cancers",
      "excerpt": "\"Compared to White people, mortality rates are two-fold higher for prostate, stomach and uterine corpus cancers in Black people.\"\n",
      "source_date": "2024-01-17",
      "source_accessed": "2026-04-11",
      "archive_url": "http://web.archive.org/web/20260411215337/https://pubmed.ncbi.nlm.nih.gov/38230766/",
      "calculation_notes": "Siegel et al. 2024 is the authoritative annual ACS peer-reviewed cancer statistics summary. The ~2x Black-vs-White prostate cancer mortality ratio is the canonical figure used for the African American row in the regional_breakdown block and the \"African ancestry\" row in personal_factor_multipliers. The gap reflects both biology (higher incidence and more aggressive disease at diagnosis in men of African descent) and differential access to timely treatment; the paper does not attempt to decompose the two contributions precisely. The overall prostate cancer death rate has been declining ~0.6% per year (per SEER), so the absolute gap is narrowing even as the ratio persists.\n",
      "independence_note": "Uses SEER incidence data and NCHS mortality data — same upstream as the SEER Stat Facts source above. Treated as a dependent but methodologically richer peer-reviewed analysis of the same pipeline.\n"
    }
  ],
  "comparison_anchors": [
    {
      "label": "All-cancer death (global adult lifetime)",
      "lifetime_us_adult": 0.14
    },
    {
      "label": "Lung cancer death (global adult lifetime)",
      "lifetime_us_adult": 0.018
    },
    {
      "label": "Colorectal cancer death (global adult lifetime)",
      "lifetime_us_adult": 0.013
    },
    {
      "label": "Breast cancer death (global adult women lifetime)",
      "lifetime_us_adult": 0.017
    },
    {
      "label": "Stroke death (global adult lifetime)",
      "lifetime_us_adult": 0.067
    },
    {
      "label": "Death in a car crash (lifetime, US)",
      "lifetime_us_adult": 0.0108
    }
  ],
  "regional_breakdown": [
    {
      "region": "Global average (men)",
      "probability": 0.02,
      "notes": "~397K deaths/yr across ~3B adult men (WCRF / IARC GLOBOCAN 2022); age-weighted global adult lifetime figure"
    },
    {
      "region": "US men",
      "probability": 0.023,
      "notes": "ACS direct SEER-based estimate: ~1 in 44 lifetime death alongside ~1 in 8 lifetime diagnosis"
    },
    {
      "region": "African American men",
      "probability": 0.04,
      "notes": "~2x higher mortality than white Americans per Siegel et al. 2024 in CA: A Cancer Journal for Clinicians; partly biology (higher incidence and more aggressive disease), partly differential access to timely screening and treatment"
    },
    {
      "region": "East Asia (men)",
      "probability": 0.005,
      "notes": "Age-standardized prostate cancer mortality is an order of magnitude lower in East Asian populations than in men of European or African descent; the gap partly survives migration, suggesting a real genetic component alongside diet and screening differences"
    },
    {
      "region": "Women (all regions)",
      "probability": 0,
      "notes": "Not anatomically possible; women do not have a prostate gland"
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "African ancestry",
      "multiplier": 2,
      "notes": "~2x higher prostate cancer mortality in Black men vs White men in the US per Siegel et al. 2024; similar elevation in Caribbean populations of African descent per ACS"
    },
    {
      "factor": "first-degree family history (father or brother with prostate cancer)",
      "multiplier": 2,
      "notes": "Roughly doubles lifetime risk; stronger if multiple relatives or early-onset diagnosis"
    },
    {
      "factor": "BRCA2 pathogenic variant carrier",
      "multiplier": 3,
      "notes": "BRCA2 is the strongest common genetic driver of aggressive prostate cancer; BRCA1 carriers have a smaller but measurable elevation"
    },
    {
      "factor": "age 70+ vs age 50 baseline",
      "multiplier": 5,
      "notes": "Prostate cancer mortality is overwhelmingly age-driven — median age at death is 79 per SEER, and roughly 6 in 10 diagnoses occur at 65 or older. The annual hazard in the 70s is several times the hazard in the 50s, and negligible before 40."
    }
  ],
  "short_label": "Prostate cancer",
  "myth_framing": "overrated",
  "outcome_severity": "fatal",
  "exposure_pattern": "recurring",
  "outcome_type": "chronic_illness",
  "valence": "negative",
  "caveats": "This entry is lifetime *mortality* from prostate cancer, not incidence. The widely quoted \"1 in 8\" figure is the lifetime probability a US man will be *diagnosed* with prostate cancer; the lifetime probability he will *die* of it is about 1 in 44 per ACS — roughly 5.5x smaller. The diagnosis/death gap is larger for prostate cancer than for any other common cancer on this site. Five-year relative survival is 97.9% per SEER, higher than for any other common cancer, and a meaningful share of older men carry histologically detectable prostate cancer that never causes symptoms: autopsy studies have found microscopic prostate cancer in a majority of men over 70 who died of unrelated causes. This is the main reason USPSTF recommendations on PSA screening have moved twice in the past fifteen years and still describe the decision as individual rather than routine — overdiagnosis and overtreatment are the dominant harms, and the mortality benefit, while real, is modest and context-dependent. Prostate cancer is also a male-only disease by anatomy, so the \"global adult\" framing of the headline number is population-weighted across the roughly half of adults at risk. For women the probability is zero; for men the population-average figure near 1 in 50 lifetime hides an enormous gap between indolent low-grade disease (where many men die *with* prostate cancer, not *of* it) and aggressive high-grade disease (where the 5-year survival drops sharply). The Black-White mortality gap is the largest demographic disparity for any common cancer in the US and is partly biological and partly structural — current evidence does not let the two contributions be cleanly separated.\n",
  "quality_score": {
    "d1": 5,
    "d2": 5,
    "d3": 4,
    "d4": 4,
    "d5": 5,
    "d6": 5,
    "d7": 5,
    "d8": 5,
    "avg": 4.75,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-05-25",
    "methodology_version": "1.2"
  },
  "reviewer": "likelier-phase-5-agent",
  "last_reviewed": "2026-04-11",
  "reviewed": true,
  "generated_at": "2026-04-11",
  "image": {
    "alt": "A large pale circle enclosing a much smaller dark circle on a muted sand background, flat vector illustration."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/prostate-cancer"
}